Connection

Adviye Ergul to Diabetes Mellitus, Type 2

Back to Details
This is a "connection" page, showing publications Adviye Ergul has written about Diabetes Mellitus, Type 2.
Adviye Ergul
Connection Strength
6.127
Diabetes Mellitus, Type 2
  1. Deferoxamine Treatment Prevents Post-Stroke Vasoregression and Neurovascular Unit Remodeling Leading to Improved Functional Outcomes in Type 2 Male Diabetic Rats: Role of Endothelial Ferroptosis. Transl Stroke Res. 2021 08; 12(4):615-630.
    View in: PubMed
    Score: 0.378
  2. Microglia knockdown reduces inflammation and preserves cognition in diabetic animals after experimental stroke. J Neuroinflammation. 2020 Apr 28; 17(1):137.
    View in: PubMed
    Score: 0.370
  3. Post-stroke neovascularization and functional outcomes differ in diabetes depending on severity of injury and sex: Potential link to hemorrhagic transformation. Exp Neurol. 2019 01; 311:106-114.
    View in: PubMed
    Score: 0.331
  4. Linagliptin treatment improves cerebrovascular function and remodeling and restores reduced cerebral perfusion in Type 2 diabetes. Am J Physiol Regul Integr Comp Physiol. 2016 09 01; 311(3):R466-77.
    View in: PubMed
    Score: 0.283
  5. Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes. Transl Res. 2014 Nov; 164(5):424-32.
    View in: PubMed
    Score: 0.246
  6. Comparative analysis of the neurovascular injury and functional outcomes in experimental stroke models in diabetic Goto-Kakizaki rats. Brain Res. 2013 Dec 06; 1541:106-14.
    View in: PubMed
    Score: 0.235
  7. Vascularization pattern after ischemic stroke is different in control versus diabetic rats: relevance to stroke recovery. Stroke. 2013 Oct; 44(10):2875-82.
    View in: PubMed
    Score: 0.232
  8. Cerebral neovascularization and remodeling patterns in two different models of type 2 diabetes. PLoS One. 2013; 8(2):e56264.
    View in: PubMed
    Score: 0.224
  9. Targets of vascular protection in acute ischemic stroke differ in type 2 diabetes. Am J Physiol Heart Circ Physiol. 2013 Mar 15; 304(6):H806-15.
    View in: PubMed
    Score: 0.223
  10. Cerebral myogenic reactivity and blood flow in type 2 diabetic rats: role of peroxynitrite in hypoxia-mediated loss of myogenic tone. J Pharmacol Exp Ther. 2012 Aug; 342(2):407-15.
    View in: PubMed
    Score: 0.213
  11. Enhanced cerebral but not peripheral angiogenesis in the Goto-Kakizaki model of type 2 diabetes involves VEGF and peroxynitrite signaling. Diabetes. 2012 Jun; 61(6):1533-42.
    View in: PubMed
    Score: 0.210
  12. Comparison of selective versus dual endothelin receptor antagonism on cerebrovascular dysfunction in diabetes. Neurol Res. 2011 Mar; 33(2):185-91.
    View in: PubMed
    Score: 0.196
  13. Endothelial endothelin B receptor-mediated prevention of cerebrovascular remodeling is attenuated in diabetes because of up-regulation of smooth muscle endothelin receptors. J Pharmacol Exp Ther. 2011 Apr; 337(1):9-15.
    View in: PubMed
    Score: 0.193
  14. Endothelin-1-mediated cerebrovascular remodeling is not associated with increased ischemic brain injury in diabetes. Can J Physiol Pharmacol. 2010 Aug; 88(8):788-95.
    View in: PubMed
    Score: 0.188
  15. Dual endothelin receptor antagonism prevents remodeling of resistance arteries in diabetes. Can J Physiol Pharmacol. 2010 Jun; 88(6):616-21.
    View in: PubMed
    Score: 0.186
  16. Adaptive cerebral neovascularization in a model of type 2 diabetes: relevance to focal cerebral ischemia. Diabetes. 2010 Jan; 59(1):228-35.
    View in: PubMed
    Score: 0.178
  17. Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1. Am J Physiol Regul Integr Comp Physiol. 2009 Apr; 296(4):R952-9.
    View in: PubMed
    Score: 0.169
  18. Differential effects of diet-induced dyslipidemia and hyperglycemia on mesenteric resistance artery structure and function in type 2 diabetes. J Pharmacol Exp Ther. 2009 Jan; 328(1):123-30.
    View in: PubMed
    Score: 0.166
  19. Impaired insulin-mediated vasorelaxation in a nonobese model of type 2 diabetes: role of endothelin-1. Can J Physiol Pharmacol. 2008 Jun; 86(6):358-64.
    View in: PubMed
    Score: 0.162
  20. Effect of chronic and selective endothelin receptor antagonism on microvascular function in type 2 diabetes. Am J Physiol Heart Circ Physiol. 2008 Jun; 294(6):H2743-9.
    View in: PubMed
    Score: 0.161
  21. Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 diabetes. Am J Physiol Regul Integr Comp Physiol. 2008 Apr; 294(4):R1213-9.
    View in: PubMed
    Score: 0.159
  22. Increased hemorrhagic transformation and altered infarct size and localization after experimental stroke in a rat model type 2 diabetes. BMC Neurol. 2007 Oct 15; 7:33.
    View in: PubMed
    Score: 0.155
  23. Differential effects of ET(A) and ET(B) receptor antagonism on oxidative stress in type 2 diabetes. Vascul Pharmacol. 2007 Aug-Sep; 47(2-3):125-30.
    View in: PubMed
    Score: 0.151
  24. Microvascular versus macrovascular dysfunction in type 2 diabetes: differences in contractile responses to endothelin-1. Exp Biol Med (Maywood). 2006 Jun; 231(6):1016-21.
    View in: PubMed
    Score: 0.141
  25. Type-2 diabetes-induced changes in vascular extracellular matrix gene expression: relation to vessel size. Cardiovasc Diabetol. 2006 Feb 17; 5:3.
    View in: PubMed
    Score: 0.138
  26. Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes. Am J Physiol Regul Integr Comp Physiol. 2006 Feb; 290(2):R435-41.
    View in: PubMed
    Score: 0.135
  27. Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1. Diabetes. 2005 Sep; 54(9):2638-44.
    View in: PubMed
    Score: 0.134
  28. Vascular endothelin converting enzyme-1 expression and activity is upregulated in clinical diabetes. Ethn Dis. 2002; 12(4):S3-5-9.
    View in: PubMed
    Score: 0.104
  29. Inhibition of Ephrin-B2 in brain pericytes decreases cerebral pathological neovascularization in diabetic rats. PLoS One. 2019; 14(1):e0210523.
    View in: PubMed
    Score: 0.084
  30. Impact of Metabolic Diseases on Cerebral Circulation: Structural and Functional Consequences. Compr Physiol. 2018 03 25; 8(2):773-799.
    View in: PubMed
    Score: 0.080
  31. Enhanced VEGF signalling mediates cerebral neovascularisation via downregulation of guidance protein ROBO4 in a rat model of diabetes. Diabetologia. 2017 04; 60(4):740-750.
    View in: PubMed
    Score: 0.074
  32. Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes. Am J Physiol Heart Circ Physiol. 2015 Jul 15; 309(2):H297-304.
    View in: PubMed
    Score: 0.065
  33. Augmented dilation to nitric oxide in uterine arteries from rats with type 2 diabetes: implications for vascular adaptations to pregnancy. Am J Physiol Heart Circ Physiol. 2014 Feb 15; 306(4):H610-8.
    View in: PubMed
    Score: 0.059
  34. Erectile dysfunction in young non-obese type II diabetic Goto-Kakizaki rats is associated with decreased eNOS phosphorylation at Ser1177. J Sex Med. 2010 Nov; 7(11):3620-34.
    View in: PubMed
    Score: 0.047
  35. Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats. J Pharmacol Exp Ther. 2009 Aug; 330(2):532-40.
    View in: PubMed
    Score: 0.043
  36. Internal pudendal artery from type 2 diabetic female rats demonstrate elevated endothelin-1-mediated constriction. J Sex Med. 2011 Sep; 8(9):2472-83.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.